In recent years, the new oral anticoagulants, direct inhibitors of the X factor (rivaroxaban, apixaban) or of the thrombin (dabigatran), have consolidated their role in the prevention of venous thromboembolism (in case of total hip replacement) as well as in the cardioembolic stroke prophylaxis (in patients with nonvalvular atrial fibrillation). Moreover, more recently, rivaroxaban and apixaban are indicated in the treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism. The most serious side effect is the gastro intestinal bleeding that, however, can be often avoided by a careful assessment of the individual patient. Here, we draw attention to an extremely rare side effect, perhaps one of the first cases described in the literature, occurred in a patient with non-valvular atrial fibrillation treated with dabigatran 110 bid for thrombo embolic prophylaxis.
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The most serious side effect is the gastro intestinal bleeding that, however, can be often avoided by a careful assessment of the individual patient. 2 Here, we draw attention to an extremely rare side effect, perhaps one of the first cases described in the literature, occurred in a patient with non-valvular atrial fibrillation treated with dabigatran 110 bid for thrombo embolic prophylaxis.
We describe the case of a patient, male, 88 years old, transported to the Emergency Department of the Assisi Hospital with intense dyspnea associated with tirage and cornage. These clinical symptoms arose two minutes after taking one capsule of 110 mg dabigatran that the patient accidentally smashed in the mouth.
Blood After an unsuccessfully initial treatment with steroids (hydrocortisone 1000 mg endovenously and aerosols beclomethasone) and b-adrenergic aerosol, the patient was treated with epinephrine (1 mg 1 fL for aerosol) resulting in clinical improvements while persisting a light dyspnea for some hours.
After the adrenaline treatment, the patient was subjected to laryngoscopy that allowed revealing an edema of the vestibule palatine and extensive edema of the vocal cords with a consequent reduction of the airspace.
The clinical scenario described above is the result of an allergic reaction to one or more component of the structure of the drug capsule. In the next months, the patient will be submitted to allergy tests in order to point out the allergen responsible of this severe reaction.
Finally, we found appropriate, especially in patients who have difficulty swallowing, to have the greatest attention to the correct method of taking the drug. 
